a Department of Neurology , Loma Linda University School of Medicine , Loma Linda , CA , USA.
b Department of Neurological Surgery , Keck School of Medicine of USC , Los Angeles , CA , USA.
Expert Rev Neurother. 2019 Apr;19(4):293-299. doi: 10.1080/14737175.2019.1592677. Epub 2019 Mar 20.
Levodopa-induced dyskinesia (LID) is a significant impediment to the long-term use of levodopa for Parkinson's disease (PD). Relatively few studies exist that have described safe and effective therapy for LID. There is thus a significant need for therapy that can control LID to allow for greater sustainability of levodopa therapy. Amantadine extended release (ER) is currently the only FDA-approved medication for the treatment of LID. While other medications have demonstrated efficacy in treating the motor symptoms of PD, amantadine ER is the only one that has been shown, in several clinical trials, to reduce LID and reduce OFF time. Areas Covered: In this review, the authors present the findings of amantadine ER including its efficacy and safety. The authors also provide their expert perspectives on its use and its future prospects. Expert opinion: Several therapies are currently being used and studied for controlling LID, an unmet need in therapy for PD. Amantadine ER has potential to supplement levodopa therapy in PD and improve patient therapeutic outcomes.
左旋多巴诱导的运动障碍（LID）是限制左旋多巴治疗帕金森病（PD）长期应用的重要因素。目前仅有少数研究描述了 LID 的安全有效治疗方法。因此，非常需要能够控制 LID 的治疗方法，以提高左旋多巴治疗的可持续性。盐酸金刚烷胺缓释剂（ER）是目前唯一被 FDA 批准用于治疗 LID 的药物。虽然其他药物已被证明在治疗 PD 的运动症状方面有效，但盐酸金刚烷胺 ER 是唯一在几项临床试验中被证明能减少 LID 和减少“OFF”时间的药物。涵盖领域：在这篇综述中，作者介绍了盐酸金刚烷胺 ER 的研究结果，包括其疗效和安全性。作者还提供了他们对该药物的使用及其未来前景的专家观点。专家意见：目前有几种治疗方法正在用于治疗和研究 LID，这是 PD 治疗中的一个未满足的需求。盐酸金刚烷胺 ER 有可能补充 PD 中的左旋多巴治疗，并改善患者的治疗效果。
